TNP-2198 Placebo

DRUG2 trials

Sponsors

TenNor Therapeutics (Suzhou) Limited

Conditions

Helicobacter Pylori Infection

Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effect of TNP-2198 Capsules After Single Oral Dose in Healthy Participants

CompletedNCT06081699

TenNor Therapeutics (Suzhou) LimitedHelicobacter Pylori Infection

Start: 2019-05-09End: 2019-09-18Updated: 2023-10-13

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TNP-2198 Capsules in Asymptomatic Participants With Helicobacter Pylori Infection

CompletedNCT06081712

TenNor Therapeutics (Suzhou) LimitedHelicobacter Pylori Infection

Start: 2020-10-20End: 2021-07-15Updated: 2023-10-13

Related Papers

Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials.

2024-02-1210 citations